financetom
CMCO
financetom
/
Industrials
/
CMCO
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Columbus McKinnon CorporationCMCO
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Columbus McKinnon Corporation designs, manufactures, and markets intelligent motion solutions for moving, lifting, positioning, and securing materials worldwide.

It offers manual hoists, electric and air hoists, winches, hydraulic jacks, trolleys and its clamps, and lifting tables; crane systems, such as mobile and jib cranes, material handling solutions, enclosed track rail systems, and crane components and kits; and rigging equipment comprising below-the-hook lifting devices, lifting slings and lashing systems, tie-downs and load binders, forestry and hand tools, and shackles.

The company also provides power and motion technology products, including linear motion products, elevator and mining drives, automation and diagnostics, brakes, radio controls, cable and festoon systems, collision avoidance systems, AC line regenerative systems, AC and DC motor control systems, conductor bar systems, inverter duty motors, pendant pushbutton stations, and wind inverters.

In addition, it offers flexible chain, industrial belt, and sanitary stainless-steel conveyors, as well as pallet system conveyors and accumulation systems, and parts and belts; rotary unions and swivel joints; and rail technology products.

The company serves various market verticals, including the manufacturing, transportation, energy and utilities, process industries, industrial automation, construction and infrastructure, food and beverage, entertainment, life sciences, consumer packaged goods, and e-commerce/supply chain/warehousing.

It offers its products to end users directly, as well as through distributors, independent crane builders, material handling specialists and integrators, original equipment manufacturers, government agencies, and engineering procurement and construction firms.

The company was founded in 1875 and is headquartered in Buffalo, New York.

Latest News >
Argentina power firm Genneia files for US IPO
Argentina power firm Genneia files for US IPO
Jul 2, 2026
July 2 (Reuters) - Argentine power producer Genneia filed for an initial public offering in the U.S. on Thursday. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Joyjeet Das) ...
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Jul 2, 2026
06:09 AM EDT, 07/02/2026 (MT Newswires) -- Toyota Motor ( TM ) will partially cover losses worth tens of billions of yen for suppliers affected by its decision to cancel the development of an electric vehicle, Nikkei Asia reported Wednesday. The cancellation of Lexus' LF-ZC sedan has hurt the company's supply chain, with some suppliers likely facing losses of up...
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Liwei Sun, Director, President, on June 30, 2026, sold 353,624 shares in Nip Group ( NIPG ) for $442,030. Following the Form 4 filing with the SEC, Sun has control over a total of 18,095,424 Class B1 ordinary shares of the company, with 18,095,424 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1966233/000149315226031618/xslF345X05/ownership.xml ...
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Hutchmed ( HCM ) said Thursday China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The company said the approval is based on a phase 2 study in which Orpathys achieved its primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved